Testing a new ventilator for adults who need breathing support in intensive care
Tests the INBENTUS VERSATILE ventilator in adults needing machine breathing support.
Plain-language title generated from the registry record
Registry title: Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning.
Key facts
- Where
- Murcia, SpainSee the site
Where in Spain
- Hospital Universitario Virgen de la ArrixacaMurcia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Iconic Solutions By Murcia SL
- Trial code
- NCT07432191
- Record updated
- 14 September 2026
- Original description
Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.Read full original descriptionShow less
Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning.
Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.
The 81 aldult participants are ventilated between 3 and 48 hours with invasive mechanical ventilation (IMV) in assisted/controlled mode and weaning under partial pressure support or volume support, followed by monitoring period until ICU discharge, hospital discharge or 30 days.
The study design differentiates between a Validation Cohort (up to 20 participants) for device validation and a Study Cohort (up to 61 participants) for safety and performance confirmation.
Serious Adverse Events related to study device and/or its procedure is defined as the primary safety endpoint, whereas technical failure rate is defined as the primary performance endpoint.
Inclusion: Participants ≥ 18 years of age at the time of consent; Participants requiring invasive mechanical ventilation for a period of ≥3 hours; Participants must provide written informed consent.
Exclusion: Participants requiring modifications to the ventilator circuit, such as those treated with nitric oxide (iNO); Any participant determined by the research team to be hemodynamically unstable, defined as:; MAP < 65 mmHg despite vasoactive drugs; Systolic Blood Pressure > 180 mmHg; Diastolic Blood Pressure > 110 mmHg; Severe volume loss (>30% of blood volume) with persistent signs of hypoperfusion; Participants requiring anesthetic delivery systems or aerosol nebulizer systems; Life expectancy of less than 12 months; Pregnant women at the time of informed consent.